Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
631 Phase I dose escalation study in patients with advanced solid tumors with ANV419, a novel fusion protein selective for IL-2Rβ/γ
Compose a Response to This Article
Other responses
No responses have been published for this article.